Serum levels of B-cell activating factor of the TNF family (BAFF) correlate with anti-Jo-1 autoantibodies levels and disease activity in patients with anti-Jo-1positive polymyositis and dermatomyositis

Table 2 Correlations between serum levels of BAFF and anti-Jo-1 antibodies with serum levels of muscle enzymes (CK and AST), myoglobin, and CRP at baseline evaluation in myositis patients and in subgroups with dermatomyositis/polymyositis, with or without lung involvement, and in patients with short disease duration

		anti-Jo-1		CK		Myoglobin		AST		CRP
		r	p	r	p	r	p	r	p	r	p
All (n = 63)	BAFF	0.42	0.0006**	0.50	< 0.0001***	0.39	0.004*	0.45	0.0003**	0.44	0.0004**
All (n = 63)	anti-Jo-1	–	–	0.47	0.0001***	0.46	0.0006**	0.28	0.03	0.38	0.003*
PM (n = 41)	BAFF	0.43	0.005*	0.63	< 0.0001***	0.42	0.01	0.43	0.006*	0.48	0.002*
PM (n = 41)	anti-Jo-1	–	–	0.44	0.004*	0.46	0.006*	0.18	0.26	0.41	0.01
ILD (n = 48)	BAFF	0.38	0.008	0.49	< 0.0001***	0.40	0.01	0.46	0.001*	0.44	0.003*
ILD (n = 48)	anti-Jo-1	–	–	0.49	< 0.0001***	0.58	< 0.0001***	0.30	0.04	0.47	0.001*
Early (n = 30)	BAFF	0.57	0.001*	0.63	0.0002**	0.55	0.0025*	0.61	0.0003**	0.41	0.03
Early (n = 30)	anti-Jo-1	–	–	0.69	< 0.0001***	0.74	< 0.0001***	0.56	0.001*	0.34	0.06

AST aspartate aminotransferase, BAFF B-cell activating factor of the tumour necrosis factor family, CK creatine kinase, CRP C-reactive protein, Early early case, defined as duration up to 6 months from diagnosis, ILD interstitial lung disease, PM polymyositis
p = p value; *alfa = 0.05 (0.006 after Bonferroni correction); **alfa = 0.01 (0.001 after Bonferroni correction); ***alfa = 0.001 (0.0001 after Bonferroni correction)

ISSN: 1478-6362